CMS Open Payments · Tool
Boehringer Ingelheim Pharmaceuticals, Inc. vs AstraZeneca UK Limited
Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.
A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.
Compare Different Companies
Relationship comparison
Which recorded payment profile is more concentrated?
AstraZeneca UK Limited has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 5,304, versus 34 for the other company. Its single largest recorded recipient represents 72.7% of that company's General Payments recipient total.
HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- HHI 34 · top recipient 3.6%
- Ranked #1,789 of 1,838 companies by HHI
- AstraZeneca UK Limited
- HHI 5,304 · top recipient 72.7%
- Ranked #314 of 1,838 companies by HHI
Payment Overview
- Total Payments
- $148.9M
- % of Industry
- 1.1%
- Transactions
- 218,635
- Avg per Transaction
- $681.03
- Recipients
- 216,716
- Avg per Recipient
- $687.06
- Payment Types
- 8
- Top Payment Type
- Compensation for Services Other Than Consulting
AstraZeneca UK Limited
- Total Payments
- $124.7M
- % of Industry
- 0.9%
- Transactions
- 4,340
- Avg per Transaction
- $28.7K
- Recipients
- 2,367
- Avg per Recipient
- $52.7K
- Payment Types
- 7
- Top Payment Type
- Royalty or License
Highlighted values indicate the higher figure for each metric.
Total payments compared
Boehringer Ingelheim Pharmaceuticals, Inc. vs AstraZeneca UK Limited - total reported payments in CMS Open Payments PY2024
General Payment Types Breakdown
Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.
Boehringer Ingelheim Pharmaceuticals, Inc.
39.5%
28.2%
18.4%
5.4%
3.2%
2.9%
AstraZeneca UK Limited
73.2%
20.7%
2.7%
1.9%
1.2%
0.3%
Top 5 General-Payment Recipients
This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.
Boehringer Ingelheim Pharmaceuticals, Inc.
- 1
RUSSELL LEE CARLISLE
$642,009.64 · 11 txns
- 2
Hospital Of The Univ Of Penna
$520,426.71 · 12 txns
- 3
Univ Of Mi Hospitals & Hlth Ctrs
$288,636.64 · 10 txns
- 4
University Of Washington Med Ctr
$187,794.81 · 6 txns
- 5
Beth Israel Deaconess Medical Center
$148,000.00 · 2 txns
AstraZeneca UK Limited
- 1
Dana-farber Cancer Institute
$11,211,159.75 · 4 txns
- 2
David Linneus Horn
$571,707.50 · 6 txns
- 3
Univ Of Mi Hospitals & Hlth Ctrs
$273,026.00 · 1 txns
- 4
CHRISTOPHER B COOPER
$101,693.30 · 22 txns
- 5
JEFFREY Paul KANNE
$87,250.00 · 9 txns
Summary Comparison
| Metric | Boehringer Ingelheim Pharmaceuticals, Inc. | AstraZeneca UK Limited |
|---|---|---|
| Total Payments | $148.9M | $124.7M |
| % of Industry Total | 1.1% | 0.9% |
| Transaction Count | 218,635 | 4,340 |
| Avg per Transaction | $681.03 | $28.7K |
| Recipient Count | 216,716 | 2,367 |
| Avg per Recipient | $687.06 | $52.7K |
| Payment Type Count | 8 | 7 |
| Top Payment Type | Compensation for Services Other Than Consulting | Royalty or License |
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.